BIAF Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.55M

-29.65%

-2.700

-57.14%

1.48M

-19.99%

-2.400

-50%

1.70M

+33.99%

-2.100

-58.82%

Estimates Revision

The market is revising No Change the revenue expectations for bioAffinity Technologies, Inc. (BIAF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -51.10%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-51.10%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for bioAffinity Technologies Inc (BIAF.O) is -0.13, compared to its 5-year average forward P/E of -1.93. For a more detailed relative valuation and DCF analysis to assess bioAffinity Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.93

Current PE

-0.13

Overvalued PE

-0.91

Undervalued PE

-2.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.99

Current PS

0.83

Overvalued PS

1.94

Undervalued PS

0.03

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BIAF News & Events

Events Timeline

No data

News

3.5

2025-12-03Newsfilter

bioAffinity Showcases CyPath® Lung Cancer Detection Technology with 92% Sensitivity

7.5

2025-11-05Newsfilter

bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume

8.5

2025-10-09Newsfilter

bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations

People Also Watch

Frequently Asked Questions

What is bioAffinity Technologies Inc (BIAF) stock price today?

The current price of BIAF is 1.33 USD — it has increased 3.1 % in the last trading day.

What is bioAffinity Technologies Inc (BIAF)'s business?

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

What is the price predicton of BIAF Stock?

Wall Street analysts forecast BIAF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is bioAffinity Technologies Inc (BIAF)'s revenue for the last quarter?

bioAffinity Technologies Inc revenue for the last quarter amounts to 1.45M USD, decreased -38.48 % YoY.

What is bioAffinity Technologies Inc (BIAF)'s earnings per share (EPS) for the last quarter?

bioAffinity Technologies Inc. EPS for the last quarter amounts to -4.74 USD, decreased -2.07 % YoY.

What changes have occurred in the market's expectations for bioAffinity Technologies Inc (BIAF)'s fundamentals?

How many employees does bioAffinity Technologies Inc (BIAF). have?

bioAffinity Technologies Inc (BIAF) has 57 emplpoyees as of January 10 2026.

What is bioAffinity Technologies Inc (BIAF) market cap?

Today BIAF has the market capitalization of 5.98M USD.